CONTACT US:
    (805) 483 1185

All fields are required.

Close Appointment form

    CONTACT US:
    (805) 483 1185

    A phase 3 study for chikungunya vaccine after passing midstage test

    • Home
    • A phase 3 study for chikungunya vaccine after passing midstage test
    A phase 3 study for chikungunya vaccine after passing midstage test
    A phase 3 study for chikungunya vaccine after passing midstage test

    No Comments

    A phase 3 study for chikungunya vaccine after passing midstage test

    The chikungunya vaccine, known as MV-CHIK, hit its primary goal in the phase 2 trial, and Themis is now eyeing a move into phase 3. The company based its chikungunya shot on its measles vector platform, licensed from Institut Pasteur.

    • Share This

    Related Posts

    Submit a comment

    Your email address will not be published. Required fields are marked *

    Leave a Reply

    You may use these HTML tags and attributes:

    <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>